Académique Documents
Professionnel Documents
Culture Documents
Note: These recommendations must be read with the footnotes that follow
containing number of doses, intervals between doses, and other important information.
Figure 1. Recommended adult immunization schedule, by vaccine and age group1
VACCINE
Influenza
19-21 years
AGE GROUP
22-26 years
27-49 years
50-59 years
2 doses
3 doses
3 doses
1 dose
1 or 2 doses
7,*
65 years
Substitute 1-time dose of Tdap for Td booster; then boost with Td every 10 yrs
3,*
Varicella 4,*
Zoster
60-64 years
1 dose annually
2,*
8,*
1 dose
1 or 2 doses
9,10
1 dose
1 or more doses
11,*
12,*
2 doses
Hepatitis B 13,*
3 doses
1 or 3 doses
Report all clinically significant postvaccination reactions to the Vaccine Adverse Event Reporting System (VAERS). Reporting forms and instructions on filing
a VAERS report are available at www.vaers.hhs.gov or by telephone, 800-822-7967.
Information on how to file a Vaccine Injury Compensation Program claim is available at www.hrsa.gov/vaccinecompensation or by telephone, 800-338-2382.
To file a claim for vaccine injury, contact the U.S. Court of Federal Claims, 717 Madison Place, N.W., Washington, D.C. 20005; telephone, 202-357-6400.
Additional information about the vaccines in this schedule, extent of available data, and contraindications for vaccination is also available at
www.cdc.gov/vaccines or from the CDC-INFO Contact Center at 800-CDC-INFO (800-232-4636) in English and Spanish, 8:00 a.m. - 8:00 p.m. Eastern
Time, Monday - Friday, excluding holidays.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
The recommendations in this schedule were approved by the Centers for Disease Control and Preventions (CDC) Advisory Committee on Immunization
Practices (ACIP), the American Academy of Family Physicians (AAFP), the American College of Physicians (ACP), American College of Obstetricians and
Gynecologists (ACOG) and American College of Nurse-Midwives (ACNM).
Figure 2. Vaccines that might be indicated for adults based on medical and other indications1
VACCINE
HIV infection
Heart
Asplenia (including
Immunodisease,
elective splenectomy
compromising CD4+ T lymphocyte
4,6,7,8,15
count
Men who Kidney failure,
chronic
and persistent
conditions
have sex end-stage renal lung disease,
complement
Chronic
(excluding human
with men disease, receipt
chronic
component
liver
Healthcare
immunodeficiency < 200 200
(MSM) of hemodialysis alcoholism
deficiencies) 8,14
disease Diabetes personnel
INDICATION Pregnancy virus [HIV])4,6,7,8,15 cells/L cells/L
Influenza 2,*
Tetanus, diphtheria, pertussis (Td/Tdap) 3,*
1 dose IIV or
LAIV annually
Substitute 1-time dose of Tdap for Td booster; then boost with Td every 10 yrs
Contraindicated
Varicella 4,*
2 doses
Contraindicated
Zoster 6
1 dose
Contraindicated
1 or 2 doses
1 dose
8,*
1 or 2 doses
1 or more doses
Meningococcal 11,*
Hepatitis A 12,*
2 doses
Hepatitis B 13,*
3 doses
For all persons in this category who meet the age requirements and who
lack documentation of vaccination or have no evidence of previous infection;
zoster vaccine recommended regardless of prior episode of zoster
1 or 3 doses
Recommended if some other risk factor
is present (e.g., on the basis of medical,
occupational, lifestyle, or other indications)
No recommendation
These schedules indicate the recommended age groups and medical indications for which administration of currently licensed vaccines is commonly
indicated for adults ages 19 years and older, as of February 1, 2014. For all vaccines being recommended on the Adult Immunization Schedule:
a vaccine series does not need to be restarted, regardless of the time that has elapsed between doses. Licensed combination vaccines may be
used whenever any components of the combination are indicated and when the vaccines other components are not contraindicated. For detailed
recommendations on all vaccines, including those used primarily for travelers or that are issued during the year, consult the manufacturers package
inserts and the complete statements from the Advisory Committee on Immunization Practices (www.cdc.gov/vaccines/hcp/acip-recs/index.html). Use of
trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
Footnotes
Recommended Immunization Schedule for Adults Aged 19 Years or Older: United States, 2014
1. Additional information
Additional guidance for the use of the vaccines described in this supplement
is available at www.cdc.gov/vaccines/hcp/acip-recs/index.html.
Information on vaccination recommendations when vaccination status is
unknown and other general immunization information can be found in
the General Recommendations on Immunization at
www.cdc.gov/mmwr/preview/mmwrhtml/rr6002a1.htm.
Information on travel vaccine requirements and recommendations (e.g.,
for hepatitis A and B, meningococcal, and other vaccines) is available at
http://wwwnc.cdc.gov/travel/destinations/list.
Additional information and resources regarding vaccination of pregnant women
can be found at http://www.cdc.gov/vaccines/adults/rec-vac/pregnant.html.
2. Influenza vaccination
Annual vaccination against influenza is recommended for all persons
aged 6 months or older.
Persons aged 6 months or older, including pregnant women and persons
with hives-only allergy to eggs, can receive the inactivated influenza
vaccine (IIV). An age-appropriate IIV formulation should be used.
Adults aged 18 to 49 years can receive the recombinant influenza vaccine
(RIV) (FluBlok). RIV does not contain any egg protein.
Healthy, nonpregnant persons aged 2 to 49 years without high-risk medical
conditions can receive either intranasally administered live, attenuated
influenza vaccine (LAIV) (FluMist), or IIV. Health care personnel who care
for severely immunocompromised persons (i.e., those who require care in
a protected environment) should receive IIV or RIV rather than LAIV.
The intramuscularly or intradermally administered IIV are options for
adults aged 18 to 64 years.
Adults aged 65 years or older can receive the standard-dose IIV or the
high-dose IIV (Fluzone High-Dose).
3. Tetanus, diphtheria, and acellular pertussis (Td/Tdap) vaccination
Administer 1 dose of Tdap vaccine to pregnant women during each
pregnancy (preferred during 27 to 36 weeks gestation) regardless of
interval since prior Td or Tdap vaccination.
Persons aged 11 years or older who have not received Tdap vaccine
or for whom vaccine status is unknown should receive a dose of Tdap
followed by tetanus and diphtheria toxoids (Td) booster doses every 10
years thereafter. Tdap can be administered regardless of interval since
the most recent tetanus or diphtheria-toxoid containing vaccine.
Adults with an unknown or incomplete history of completing a 3-dose
primary vaccination series with Td-containing vaccines should begin or
complete a primary vaccination series including a Tdap dose.
For unvaccinated adults, administer the first 2 doses at least 4 weeks apart
and the third dose 6 to 12 months after the second.
For incompletely vaccinated (i.e., less than 3 doses) adults, administer
remaining doses.
Refer to the ACIP statement for recommendations for administering Td/
Tdap as prophylaxis in wound management (see footnote 1).
4. Varicella vaccination
All adults without evidence of immunity to varicella (as defined below)
should receive 2 doses of single-antigen varicella vaccine or a second
dose if they have received only 1 dose.
Vaccination should be emphasized for those who have close contact
with persons at high risk for severe disease (e.g., health care personnel
and family contacts of persons with immunocompromising conditions)
or are at high risk for exposure or transmission (e.g., teachers; child
care employees; residents and staff members of institutional settings,
including correctional institutions; college students; military personnel;
adolescents and adults living in households with children; nonpregnant
women of childbearing age; and international travelers).
Pregnant women should be assessed for evidence of varicella immunity.
Women who do not have evidence of immunity should receive the first
dose of varicella vaccine upon completion or termination of pregnancy
and before discharge from the health care facility. The second dose should
be administered 4 to 8 weeks after the first dose.
Evidence of immunity to varicella in adults includes any of the following:
documentation of 2 doses of varicella vaccine at least 4 weeks apart;
U.S.-born